Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases

Catechols in post-mortem brain of patients with Parkinson disease

(2010) D. S. Goldstein et al.   EUROPEAN JOURNAL OF NEUROLOGY

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson’s disease

(2010) Gessica Sala et al.   JOURNAL OF NEURAL TRANSMISSION

In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133

(2010) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

Products of Oxidative Stress Inhibit Aldehyde Oxidation and Reduction Pathways in Dopamine Catabolism Yielding Elevated Levels of a Reactive Intermediate

(2009) Yunden Jinsmaa et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Cardiac sympathetic neuroimaging: summary of the First International Symposium

(2009) David S. Goldstein et al.   CLINICAL AUTONOMIC RESEARCH

Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity

(2009) T. N. Taylor et al.   JOURNAL OF NEUROSCIENCE

Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons

(2009) Eugene V. Mosharov et al.   NEURON

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

(2008) Dennis W. Dickson et al.   ACTA NEUROPATHOLOGICA

Mitochondrial Complex I Inhibitor Rotenone Inhibits and Redistributes Vesicular Monoamine Transporter 2 via Nitration in Human Dopaminergic SH-SY5Y Cells

(2008) M. Watabe et al.   MOLECULAR PHARMACOLOGY

Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism

(2008) Yan Sai et al.   TOXICOLOGY IN VITRO